The FDA on March 28, 2025, expanded the indication for PLUVICTO® to include adults with Prostate-Specific Membrane Antigen (PSMA)-positive metastatic Castration-Resistant Prostate Cancer (mCRPC) who have been treated with Androgen Receptor Pathway Inhibitor (ARPI) therapy and are considered appropriate to delay Taxane-based chemotherapy. PLUVICTO® is a product of Novartis Pharmaceuticals Corporation.
Bottom Ad
Advertisement
Subscribe
